GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Forward Rate of Return (Yacktman) %

Nuo Therapeutics (Nuo Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Nuo Therapeutics's forward rate of return for was 0.00%.

The historical rank and industry rank for Nuo Therapeutics's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 13 years, Nuo Therapeutics's highest Forward Rate of Return was 6.41. The lowest was -46.32. And the median was 6.41.

AURX's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.72
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Nuo Therapeutics Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Nuo Therapeutics's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Forward Rate of Return (Yacktman) % Chart

Nuo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nuo Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuo Therapeutics's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Nuo Therapeutics's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Forward Rate of Return (Yacktman) % falls into.



Nuo Therapeutics Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Nuo Therapeutics's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.55+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuo Therapeutics  (OTCPK:AURX) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Nuo Therapeutics Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713